Form 4: LMAT CEO Sells Shares, Vests PSUs

LeMaitre Vascular's Chairman and CEO, George W. LeMaitre, reported significant stock sales and the vesting of performance share units.

Summary

• George W. LeMaitre, Chairman and CEO of LeMaitre Vascular Inc., reported multiple transactions involving company common stock.
• Sold 150,000 shares on February 26, 2026, at a weighted average price of $106.7557, executed under a 10b5-1(c) plan adopted on March 10, 2025.
• Acquired 5,609 shares on February 26, 2026, from the vesting of a Performance Share Unit (PSU) award granted on December 6, 2024, with 25% vesting upon performance condition satisfaction.
• Acquired 13 shares on February 26, 2026, upon the release of dividend equivalent rights.
• Disposed of 496 shares on February 26, 2026, at $113.69 to satisfy tax withholding obligations incurred upon the vesting of PSUs.
• Gifted 5,000 shares on March 2, 2026.
• Sold an additional 55,930 shares on March 2, 2026, at a weighted average price of $107.8137.
• Following these transactions, direct beneficial ownership stands at 1,476,500 shares, with an additional 33,400 shares held indirectly in an irrevocable trust.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal due to the significant volume of insider selling by the CEO, despite some transactions being pre-planned, which could suggest a lack of strong conviction or a move to diversify personal holdings.

Positives

• Vesting of 5,609 Performance Share Units (PSUs) indicates the satisfaction of performance conditions for a portion of the award.
• Acquisition of 13 shares from dividend equivalent rights.

Negatives

• Significant sales of common stock by the Chairman and CEO, totaling 205,930 shares across two transactions.
• Disposal of 5,000 shares as a gift.

Future Outlook

No specific future outlook or guidance is provided in this insider transaction report.

Industry Context

StockSavvy.ai notes that insider sales, even those pre-planned under 10b5-1, are often scrutinized by the market for potential signals regarding management's confidence in future company performance, especially when involving a CEO. Such transactions can influence investor sentiment in the medical device industry.

Comparison to Industry Standards

• Form 4 filings are specific to individual insider transactions and do not typically provide data for direct comparison to industry-wide financial benchmarks or competitor project results.

Related Party Transactions

• 33,400 shares are held indirectly by the LEMAITRE IRREVOCABLE LIFE INSURANCE TRUST OF 2025 for the benefit of the Reporting Person's child(ren). The Reporting Person disclaims ownership except for pecuniary interest.

Stakeholder Impact

• Shareholders: May interpret the significant insider selling as a negative signal, potentially impacting stock price sentiment.
• Employees: No direct impact on employees is mentioned.
• Customers: No direct impact on customers is mentioned.
• Suppliers: No direct impact on suppliers is mentioned.
• Creditors: No direct impact on creditors is mentioned.

Next Steps

• The balance of the Performance Share Unit (PSU) award granted on December 6, 2024, will vest in equal annual installments on the grant date anniversary over the next three years.

Key Dates

Recommendation

While the significant insider selling by the CEO could be a negative signal, some sales were pre-planned under a 10b5-1 plan, which mitigates the immediate negative interpretation. The vesting of PSUs also indicates some positive performance. Investors should hold and monitor future insider activity and company performance rather than making an immediate sell decision based solely on these transactions.

Keywords

LeMaitre Vascular, LMAT, Insider Trading, Form 4, Stock Sale, CEO, Performance Share Units, 10b5-1 Plan, Beneficial Ownership